Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

22 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical Perspective on Human Immunodeficiency Virus Care of Ukrainian War Refugees in Poland.
Parczewski M, Jabłonowska E, Wójcik-Cichy K, Zhyvytsia D, Witak-Jędra M, Leszczyszyn-Pynka M, Aksak-Wąs B, Siwak E, Cielniak I, Olczak A, Szymczak A, Szetela B, Bociąga-Jasik M, Kalinowska-Nowak A, Mularska E, Witor A, Jakubowski P, Hlebowicz M, Rozpłochowski B, Łojewski W, Scheibe K, Serwin K. Parczewski M, et al. Among authors: witor a. Clin Infect Dis. 2023 May 24;76(10):1708-1715. doi: 10.1093/cid/ciad116. Clin Infect Dis. 2023. PMID: 36888680
Circulation of Human Immunodeficiency Virus 1 A6 Variant in the Eastern Border of the European Union-Dynamics of the Virus Transmissions Between Poland and Ukraine.
Serwin K, Chaillon A, Scheibe K, Urbańska A, Aksak-Wąs B, Ząbek P, Siwak E, Cielniak I, Jabłonowska E, Wójcik-Cichy K, Jakubowski P, Bociąga-Jasik M, Witor A, Szetela B, Parczewski M. Serwin K, et al. Among authors: witor a. Clin Infect Dis. 2023 May 24;76(10):1716-1724. doi: 10.1093/cid/ciad058. Clin Infect Dis. 2023. PMID: 36857116
Phylodynamic evolution of HIV-1 A6 sub-subtype epidemics in Poland.
Serwin K, Scheibe K, Urbańska A, Aksak-Wąs B, Karasińska-Cieślak M, Ząbek P, Siwak E, Cielniak I, Jabłonowska E, Wójcik-Cichy K, Jakubowski P, Bociąga-Jasik M, Witor A, Szymczak A, Szetela B, Parczewski M. Serwin K, et al. Among authors: witor a. J Med Virol. 2024 Feb;96(2):e29482. doi: 10.1002/jmv.29482. J Med Virol. 2024. PMID: 38381668
Molecular epidemiology and HIV-1 variant evolution in Poland between 2015 and 2019.
Serwin K, Urbańska A, Scheibe K, Witak-Jędra M, Jankowska M, Hlebowicz M, Bociąga-Jasik M, Kalinowska-Nowak A, Biała M, Ciepłucha H, Łojewski W, Olczak A, Jabłonowska E, Kowalczuk-Kot A, Rozpłochowski B, Witor A, Parczewski M. Serwin K, et al. Among authors: witor a. Sci Rep. 2021 Aug 16;11(1):16609. doi: 10.1038/s41598-021-96125-w. Sci Rep. 2021. PMID: 34400726 Free PMC article.
HCV resistance-associated substitutions following direct-acting antiviral therapy failure - Real-life data from Poland.
Parczewski M, Janczewska E, Pisula A, Dybowska D, Łojewski W, Witor A, Wawrzynowicz-Syczewska M, Socha Ł, Krygier R, Knysz B, Musialik J, Urbańska A, Scheibe K, Jaroszewicz J. Parczewski M, et al. Among authors: witor a. Infect Genet Evol. 2021 Sep;93:104949. doi: 10.1016/j.meegid.2021.104949. Epub 2021 Jun 1. Infect Genet Evol. 2021. PMID: 34087494
Week 48 Resistance Analyses of the Once-Daily, Single-Tablet Regimen Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in Adults Living with HIV-1 from the Phase III Randomized AMBER and EMERALD Trials.
Lathouwers E, Wong EY, Brown K, Baugh B, Ghys A, Jezorwski J, Mohsine EG, Van Landuyt E, Opsomer M, De Meyer S; AMBER and EMERALD Study Groups. Lathouwers E, et al. AIDS Res Hum Retroviruses. 2020 Jan;36(1):48-57. doi: 10.1089/AID.2019.0111. Epub 2019 Oct 21. AIDS Res Hum Retroviruses. 2020. PMID: 31516033 Free PMC article. Clinical Trial.
Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1.
Eron JJ, Orkin C, Cunningham D, Pulido F, Post FA, De Wit S, Lathouwers E, Hufkens V, Jezorwski J, Petrovic R, Brown K, Van Landuyt E, Opsomer M; EMERALD study group. Eron JJ, et al. Antiviral Res. 2019 Oct;170:104543. doi: 10.1016/j.antiviral.2019.104543. Epub 2019 Jul 4. Antiviral Res. 2019. PMID: 31279073 Free article. Clinical Trial.
Long-term trends in HIV care entry: over 15 years of clinical experience from Poland.
Siwak E, Horban A, Witak-Jędra M, Cielniak I, Firląg-Burkacka E, Leszczyszyn-Pynka M, Witor A, Muller K, Bociąga-Jasik M, Kalinowska-Nowak A, Gąsiorowski J, Szetela B, Jabłonowska E, Wójcik-Cichy K, Jankowska J, Lemańska M, Olczak A, Grąbczewska E, Grzeszczuk A, Rogalska-Plonska M, Suchacz M, Mikuła T, Łojewski W, Bielec D, Kocbach P, Błudzin W, Parczewski M. Siwak E, et al. Among authors: witor a. HIV Med. 2019 Oct;20(9):581-590. doi: 10.1111/hiv.12762. Epub 2019 Jun 28. HIV Med. 2019. PMID: 31250958 Free article.
A Bivalent Meningococcal B Vaccine in Adolescents and Young Adults.
Ostergaard L, Vesikari T, Absalon J, Beeslaar J, Ward BJ, Senders S, Eiden JJ, Jansen KU, Anderson AS, York LJ, Jones TR, Harris SL, O'Neill R, Radley D, Maansson R, Prégaldien JL, Ginis J, Staerke NB, Perez JL; B1971009 and B1971016 Trial Investigators. Ostergaard L, et al. N Engl J Med. 2017 Dec 14;377(24):2349-2362. doi: 10.1056/NEJMoa1614474. N Engl J Med. 2017. PMID: 29236639 Free article. Clinical Trial.
Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial.
Orkin C, Molina JM, Negredo E, Arribas JR, Gathe J, Eron JJ, Van Landuyt E, Lathouwers E, Hufkens V, Petrovic R, Vanveggel S, Opsomer M; EMERALD study group. Orkin C, et al. Lancet HIV. 2018 Jan;5(1):e23-e34. doi: 10.1016/S2352-3018(17)30179-0. Epub 2017 Oct 6. Lancet HIV. 2018. PMID: 28993180 Clinical Trial.
22 results